MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - PIRAMAL ENTERPRISES
AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
PIRAMAL ENTERPRISES 
Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More
Current Valuations
| AUROBINDO PHARMA | PIRAMAL ENTERPRISES | AUROBINDO PHARMA/ PIRAMAL ENTERPRISES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.2 | 17.6 | 109.1% | View Chart |
| P/BV | x | 3.9 | 1.2 | 325.1% | View Chart |
| Dividend Yield | % | 0.3 | 1.9 | 14.0% |
Financials
 AUROBINDO PHARMA  PIRAMAL ENTERPRISES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-19 |
PIRAMAL ENTERPRISES Mar-19 |
AUROBINDO PHARMA/ PIRAMAL ENTERPRISES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 830 | 3,303 | 25.1% | |
| Low | Rs | 527 | 1,797 | 29.3% | |
| Sales per share (Unadj.) | Rs | 333.9 | 716.5 | 46.6% | |
| Earnings per share (Unadj.) | Rs | 40.4 | 79.7 | 50.6% | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 107.9 | 48.0% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 28.00 | 8.9% | |
| Dividend yield (eoy) | % | 0.4 | 1.1 | 33.5% | |
| Book value per share (Unadj.) | Rs | 237.1 | 1,477.5 | 16.0% | |
| Shares outstanding (eoy) | m | 585.91 | 184.45 | 317.7% | |
| Bonus/Rights/Conversions | ESOP | IS | - | ||
| Price / Sales ratio | x | 2.0 | 3.6 | 57.1% | |
| Avg P/E ratio | x | 16.8 | 32.0 | 52.6% | |
| P/CF ratio (eoy) | x | 13.1 | 23.6 | 55.5% | |
| Price / Book Value ratio | x | 2.9 | 1.7 | 165.9% | |
| Dividend payout | % | 6.2 | 35.1 | 17.6% | |
| Avg Mkt Cap | Rs m | 397,569 | 470,292 | 84.5% | |
| No. of employees | `000 | 17.9 | 7.8 | 228.3% | |
| Total wages/salary | Rs m | 25,849 | 22,504 | 114.9% | |
| Avg. sales/employee | Rs Th | 10,956.9 | 16,899.4 | 64.8% | |
| Avg. wages/employee | Rs Th | 1,447.7 | 2,877.7 | 50.3% | |
| Avg. net profit/employee | Rs Th | 1,324.3 | 1,879.9 | 70.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 195,636 | 132,153 | 148.0% | |
| Other income | Rs m | 1,553 | 3,128 | 49.7% | |
| Total revenues | Rs m | 197,189 | 135,281 | 145.8% | |
| Gross profit | Rs m | 39,519 | 66,290 | 59.6% | |
| Depreciation | Rs m | 6,680 | 5,202 | 128.4% | |
| Interest | Rs m | 2,626 | 44,097 | 6.0% | |
| Profit before tax | Rs m | 31,767 | 20,119 | 157.9% | |
| Minority Interest | Rs m | 27 | 3,194 | 0.8% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
| Tax | Rs m | 7,269 | 8,611 | 84.4% | |
| Profit after tax | Rs m | 23,645 | 14,701 | 160.8% | |
| Gross profit margin | % | 20.2 | 50.2 | 40.3% | |
| Effective tax rate | % | 22.9 | 42.8 | 53.5% | |
| Net profit margin | % | 12.1 | 11.1 | 108.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 153,645 | 122,742 | 125.2% | |
| Current liabilities | Rs m | 120,429 | 310,810 | 38.7% | |
| Net working cap to sales | % | 17.0 | -142.3 | -11.9% | |
| Current ratio | x | 1.3 | 0.4 | 323.1% | |
| Inventory Days | Days | 135 | 23 | 586.1% | |
| Debtors Days | Days | 64 | 39 | 164.0% | |
| Net fixed assets | Rs m | 103,909 | 116,904 | 88.9% | |
| Share capital | Rs m | 586 | 369 | 158.8% | |
| "Free" reserves | Rs m | 138,322 | 272,161 | 50.8% | |
| Net worth | Rs m | 138,908 | 272,530 | 51.0% | |
| Long term debt | Rs m | 1,800 | 270,196 | 0.7% | |
| Total assets | Rs m | 264,544 | 856,261 | 30.9% | |
| Interest coverage | x | 13.1 | 1.5 | 899.4% | |
| Debt to equity ratio | x | 0 | 1.0 | 1.3% | |
| Sales to assets ratio | x | 0.7 | 0.2 | 479.2% | |
| Return on assets | % | 9.9 | 6.9 | 144.6% | |
| Return on equity | % | 17.0 | 5.4 | 315.6% | |
| Return on capital | % | 23.8 | 12.4 | 191.9% | |
| Exports to sales | % | 49.6 | 0 | - | |
| Imports to sales | % | 18.8 | 0 | - | |
| Exports (fob) | Rs m | 97,091 | NA | - | |
| Imports (cif) | Rs m | 36,741 | NA | - | |
| Fx inflow | Rs m | 97,316 | 15,200 | 640.2% | |
| Fx outflow | Rs m | 40,589 | 4,889 | 830.2% | |
| Net fx | Rs m | 56,727 | 10,312 | 550.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,220 | -115,975 | -14.0% | |
| From Investments | Rs m | -28,768 | -8,265 | 348.1% | |
| From Financial Activity | Rs m | 19,191 | 107,525 | 17.8% | |
| Net Cashflow | Rs m | 6,656 | -16,650 | -40.0% | |
Share Holding
| Indian Promoters | % | 54.1 | 52.9 | 102.3% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.0 | 4.0 | 198.8% | |
| FIIs | % | 27.7 | 26.6 | 104.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 16.5 | 61.8% | |
| Shareholders | 69,601 | 93,274 | 74.6% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: DR. REDDYS LAB STERLING BIOTECH JUBILANT LIFE SCIENCES VENUS REMEDIES IPCA LABS
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Flat; Healthcare and Metal Stocks Witness Selling(Closing)
After staging a gap-down opening, Indian share markets recovered losses as the session progressed and ended on a flat note.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)
Feb 5, 2020 | Updated on Feb 5, 2020For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMost Popular
Large Opportunities Are Coming Our Way
Aug 5, 2020Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.
Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)
Aug 10, 2020Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?
Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)
Aug 6, 2020Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.
This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)
Jul 31, 2020The real reason why gold prices will go up more.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
AUROBINDO PHARMA SHARE PRICE
Aug 12, 2020 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - STRIDES PHARMA SCIENCE COMPARISON
COMPARE AUROBINDO PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.